Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002824 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy in Treating Patients With Primary Brain Tumors
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002824: Completed Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT00002824 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002824, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Inserting the gene for herpes virus into a person's cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy using antiviral drugs such as ganciclovir. PURPOSE: Phase I trial to study the effectivenesss of gene therapy in treating patients with primary brain tumors.
Interventions
- PROCEDURE conventional surgery
- DRUG chemotherapy
- DRUG ganciclovir
- BIOLOGICAL gene therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-02 |
| Phase | Phase 1 |
What the finished NCT00002824 record still lists
NCT00002824 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which conventional surgery is the first listed.
NCT00002824 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002824 about?
NCT00002824 is a clinical study titled "Gene Therapy in Treating Patients With Primary Brain Tumors". RATIONALE: Inserting the gene for herpes virus into a person's cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy using antiviral drugs such as ganciclovir. PURPOSE: Phase I trial to study the effectivenesss of gene therapy in treating patients wi...
What is the current status of trial NCT00002824?
This trial is currently completed. It is a Phase 1 study. The study started on 1996-02.
What interventions are being tested in trial NCT00002824?
The interventions under investigation include: conventional surgery (PROCEDURE), chemotherapy (DRUG), ganciclovir (DRUG), gene therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002824?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia